Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
Open Access
- 4 November 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (21) , 13499
Abstract
Randomized controlled trials (RCTs) show that decreases in low-density lipoprotein cholesterol (LDL-C) by the use of statins cause a significant reduction in the development of cardiovascular disease (CVD). However, one of our previous studies showed that, among eight RCTs that investigated the effect of statins vs. a placebo on CVD development, 56–79% of patients had residual CVD risk after the trials. In three RCTs that investigated the effect of a high dose vs. a usual dose of statins on CVD development, 78–87% of patients in the high-dose statin arms still had residual CVD risk. The risk of CVD development remains even when statins are used to strongly reduce LDL-C, and this type of risk is now regarded as statin residual CVD risk. Our study shows that elevated triglyceride (TG) levels, reduced high-density lipoprotein cholesterol (HDL-C), and the existence of obesity/insulin resistance and diabetes may be important metabolic factors that determine statin residual CVD risk. Here, we discuss atherogenic lipoproteins that were not investigated in such RCTs, such as lipoprotein (a) (Lp(a)), remnant lipoproteins, malondialdehyde-modified LDL (MDA-LDL), and small-dense LDL (Sd-LDL). Lp(a) is under strong genetic control by apolipoprotein (a), which is an LPA gene locus. Variations in the LPA gene account for 91% of the variability in the plasma concentration of Lp(a). A meta-analysis showed that genetic variations at the LPA locus are associated with CVD events during statin therapy, independent of the extent of LDL lowering, providing support for exploring strategies targeting circulating concentrations of Lp(a) to reduce CVD events in patients receiving statins. Remnant lipoproteins and small-dense LDL are highly associated with high TG levels, low HDL-C, and obesity/insulin resistance. MDA-LDL is a representative form of oxidized LDL and plays important roles in the formation and development of the primary lesions of atherosclerosis. MDA-LDL levels were higher in CVD patients and diabetic patients than in the control subjects. Furthermore, we demonstrated the atherogenic properties of such lipoproteins and their association with CVD as well as therapeutic approaches.Keywords
This publication has 164 references indexed in Scilit:
- Efficacy of combination of Ezetimibe 10 mg and rosuvastatin 2.5 mg versus rosuvastatin 5 mg monotherapy for hypercholesterolemia in patients with type 2 diabetesLipids in Health and Disease, 2013
- So Many Plasminogen Receptors: Why?Journal of Biomedicine and Biotechnology, 2012
- Similarities and differences between the effects of EPA and DHA on markers of atherosclerosis in human subjectsProceedings of the Nutrition Society, 2012
- Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese SubjectsArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C)Lipids in Health and Disease, 2008
- Remnant Lipoproteins Induce Endothelial Plasminogen Activator Inhibitor-1Biochemical and Biophysical Research Communications, 2001
- Selective Retention of VLDL, IDL, and LDL in the Arterial Intima of Genetically Hyperlipidemic Rabbits In VivoArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serumBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- cDNA sequence of human apolipoprotein(a) is homologous to plasminogenNature, 1987